Loading...
XNAS
BNTC
Market cap356mUSD
Dec 05, Last price  
13.58USD
1D
3.03%
1Q
-2.37%
Jan 2017
-40.83%
IPO
-96.10%
Name

Benitec Biopharma Inc

Chart & Performance

D1W1MN
XNAS:BNTC chart
P/E
P/S
1,650.16
EPS
Div Yield, %
Shrs. gr., 5y
140.56%
Rev. gr., 5y
-54.69%
Revenues
216k
+188.00%
545,7341,017,756829,127346,506450,311455,44611,316,77797,00059,00073,00075,000216,000
Net income
-22m
L+11.19%
0000002,867,187-8,301,000-13,781,000-18,562,000-19,562,000-21,751,000
CFO
-19m
L+7.72%
-9,271,000-9,692,000-9,692,000-20,208,000-8,304,00004,790,000-7,535,000-12,832,000-15,899,000-18,012,000-19,403,000
Dividend
Jun 01, 20180.0002 USD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.
IPO date
Jul 11, 2012
Employees
18
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑062016‑06
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT